Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date01 Jan 1994 |
|
MechanismD2 receptor antagonists |
|
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jun 1974 |
Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Randomized, Double-blind, and Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome
A 12-week clinical study to evaluate the safety and efficacy of T92 in pediatric patients with Tourette Syndrome.
Pilot Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of TSUPPORT (a Traditional Chinese Medicine) for Adults With Tourette Syndrome
A 28-week single-arm trial to evaluate the efficacy, safety and tolerability of TSupport (a Traditional Chinese Medicine) for adults with Tourette Syndrome.
A Multicenter, Double-blind, Randomized and Placebo-controlled Pivotal Phase 3 Study to Evaluate the Safety and Efficacy of T89 in the Prevention and Treatment of Acute Mountain Sickness (AMS) After Rapid Ascent
The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
100 Clinical Results associated with Tasly Pharmaceuticals, Inc.
0 Patents (Medical) associated with Tasly Pharmaceuticals, Inc.
100 Deals associated with Tasly Pharmaceuticals, Inc.
100 Translational Medicine associated with Tasly Pharmaceuticals, Inc.